News &
Media
-
Neurotech International announces breakthrough results from autism study
View MoreNeurotech International has announced breakthrough results from a clinical trial of its proprietary NTI164 cannabis strain in paediatric Autism Spectrum Disorder (ASD).
-
Neurotech International (ASX:NTI) announces “breakthrough” results for medicinal cannabis study
View MoreNeurotech International (NTI) has reported that 93 per cent of patients showed symptom improvements in a recent trial of its NTI64 drug designed to treat children with autism spectrum disorder (ASD).
-
Neurotech reports clinical trial results for world first Autism Spectrum Disorder drug
View MoreThe cannabinoid based drug, licensed from Dolve Cann Global is the world’s first full-spectrum medicinal cannabis product (with less than 0.3% THC).
-
Neurotech tackles the anguish of autism with low-THC cannabis treatment
View MoreA medical dilemma in its own right – the modern treatment of the condition commonly known as ‘autism’ can come at a high cost and with debilitating side effects – something ASX-listed Neurotech International aims to change.
-
RSH, AVR, NTI: Best performing ASX healthcare equipment stocks in June
View MoreNeurotech is conducting clinical studies to assess the anti-inflammatory, neuroprotective, and neuro-modulatory activities of its proprietary NTI/Dolce cannabis strains.
-
Weed Week: Cannabis-feed for chickens and cannabis campaigner nabs Queen’s Birthday honour
View MoreThe company recently reported significant development in the preclinical research of its lead asset program, NTI164 – a proprietary cannabis strain that contains high levels of unique minor cannabinoids and less than 0.3% THC, exclusively licensed from Dolce Cann Global.
-
Neurotech International reports positive preclinical data from combination study
View MoreNeurotech International (ASX:NTI) has reported positive preclinical research demonstrating that its NTI164 can improve diclofenac efficacy at low doses.
-
ASX Health Stocks: Neurotech says its cannabis strain works well when combined with Diclofenac
View MoreNeurotech International (ASX:NTI) has today reported significant development in the preclinical research of its lead asset program, NTI164.
-
Neurotech International (ASX:NTI) sees preclinical success with combination therapies
View MoreNeurotech International (NTI) has reported preclinical research demonstrating its proprietary cannabis strain can improve Diclofenac efficacy at low doses.